Xeris Biopharma Holdings, Inc.

NASDAQ:XERS

Biotechnology

Healthcare
$16.99 +0.58%

+$0.04 today

Market cap
$3.10B
Beta
0.90
P/E (TTM)
98.7
EPS (TTM)
$0.07
52W Low $4.40High $10.08

Volume 2.76M

Average 1.66M

XERS Pre-Tax Margin

Income before tax as a percentage of revenue.

Xeris Biopharma Holdings, Inc.NASDAQ: XERS

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin widens to 2.7%

Pre-tax margin was 2.7% in Q1 FY2026, up 18.0 pp from a year earlier. On a trailing-twelve-month basis it was 3.8%, up 25.2 pp year over year. Over 3 fiscal years it widened by 87.3 pp.

Context

  • Pre-tax margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
2.7%-10.2 pp QoQ
Last fiscal yearDec 2025
0.2%+28.3 pp YoY
LTMMar 2026
3.8%+25.2 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+18.0 pp——
1 year+28.3 pp——
3 years+87.3 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
0.2%
Year-over-year change
+28.3pp

Pre-Tax Margin vs competitors

How XERS compares with its peers on the latest reported figures

  • XERS's LTM Mar 2026 pre-tax margin of 3.8% is the 2nd highest of the 6 companies compared; the peer median is -1.7%.
  • Its year-over-year change of +25.2 pp is the 3rd highest of 6, against a peer median of +7.6 pp.
  • Over three fiscal years its change of +87.3 pp compares with a peer median of +62.4 pp.
XERS Competitors Peer median
Pre-Tax Margin for XERS and competitors
Company Period LTM level YoY 3-year change
ASNDAscendis Pharma A/SLTM Sep 202622.4% +57.0 pp+1099.6 pp
XERSXeris Biopharma Holdings, Inc.LTM Mar 20263.8% +25.2 pp+87.3 pp
CORTCorcept Therapeutics IncorporatedLTM Jun 20263.2% -14.5 pp-20.2 pp
ETONEton Pharmaceuticals, Inc.LTM Mar 2026-1.7% +7.6 pp+36.7 pp
MNKDMannKind CorporationLTM Mar 2026-7.9% -19.1 pp+88.0 pp
SEPNSepterna, Inc.LTM Sep 2026-55.1% +212.4 pp—
MBXMBX Biosciences, Inc. Common StockFY2025— ——
GHRSGH Research PLCFY2025— ——
SPRBSpruce Biosciences, Inc.FY2025— ——
Peer median (excluding XERS) -1.7%+7.6 pp+62.4 pp

Competitors are the stored peer set for XERS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue49.59M110.25M163.91M203.07M291.85M
Cost of Revenue13.32M22.63M28.65M36.83M53.41M
Gross Profit36.27M87.61M135.27M166.24M238.43M
Gross Margin73.1%79.5%82.5%81.9%81.7%
Research & Development25.16M20.97M22.34M25.56M31.17M
Selling, General & Admin125.72M137.75M146.1M163.48M182.37M
Operating Expenses151.43M169.55M179.28M199.88M213.54M
Depreciation & Amortization1.88M12.67M13.16M12.63M12.16M
EBITDA(113.67M)(69.31M)(23.74M)(13.99M)12.71M
EBITDA Margin-229.2%-62.9%-14.5%-6.9%4.4%
Operating Income(115.16M)(81.94M)(44.01M)(33.65M)24.9M
Operating Margin-232.2%-74.3%-26.8%-16.6%8.5%
Interest Income313K2.58M4.75M5.32M4.74M
Interest Expense7.18M14.1M26.61M33.18M29.08M
Other Income / Expenses(7.57M)(14.14M)(19.49M)(23.46M)(24.34M)
Income Before Tax(122.73M)(96.08M)(63.5M)(57.1M)554K
Pre-Tax Margin-247.5%-87.2%-38.7%-28.1%0.2%
Income Tax Expense0(1.42M)(1.25M)(2.27M)0
Net Income(122.73M)(94.66M)(62.26M)(54.84M)554K
Net Margin-247.5%-85.9%-38.0%-27.0%0.2%
EPS (Basic)(1.55)(0.70)(0.45)(0.37)0.00
EPS (Diluted)(1.55)(0.70)(0.45)(0.37)0.00
Weighted Avg Shares79.03M135.63M137.67M146.77M160.43M
Weighted Avg Shares (Diluted)79.03M135.63M137.67M146.77M172.74M

Xeris Biopharma Holdings, Inc.

NASDAQ:XERS

Intrinsic Alpha fair value

Locked

Current Price

$16.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.